Related Experiment Video

Updated: Jun 23, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Role of carvedilol controlled-release in cardiovascular disease

Gregg C Fonarow1

  • 1Ahmanson-UCLA Cardiomyopathy Center, 10833 LeConte Avenue, Los Angeles, CA 90095-1679, USA. gfonarow@mednet.ucla.edu

Expert Review of Cardiovascular Therapy
|May 8, 2009
PubMed

Insights

Carvedilol effectively treats heart failure and improves heart function, offering significant survival benefits for post-myocardial-infarction patients. A new once-daily formulation enhances patient adherence and clinical outcomes.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Carvedilol is a beta-blocker with alpha-1 blocking properties, showing superior efficacy in heart failure compared to traditional beta-blockers.
  • It is the only agent proven to reduce mortality and morbidity in post-myocardial-infarction patients with left ventricular dysfunction.
  • Unlike other beta-blockers, carvedilol does not cause carbohydrate and lipid disturbances.

Purpose of the Study:

  • To evaluate the efficacy and safety of a new controlled-release, once-daily formulation of carvedilol.
  • To compare the new formulation with the original twice-daily formulation.
  • To assess the impact of once-daily dosing on patient adherence and clinical outcomes.

Main Methods:

  • Numerous studies were conducted to demonstrate the efficacy and safety of the once-daily formulation.
  • Comparative analyses were performed against traditional beta-blockers and the original carvedilol formulation.
  • Patient adherence and clinical outcomes were monitored in relation to dosing frequency.

Main Results:

  • The controlled-release, once-daily formulation of carvedilol demonstrated equivalent efficacy and safety to the twice-daily formulation.
  • Carvedilol showed greater efficacy than traditional beta-blockers in heart failure management.
  • Significant reductions in mortality and morbidity were observed in post-myocardial-infarction patients.

Conclusions:

  • The once-daily formulation of carvedilol offers a convenient and effective treatment option for heart failure and post-myocardial-infarction patients.
  • Improved patient adherence due to once-daily dosing is expected to enhance long-term clinical outcomes.
  • Carvedilol's unique pharmacological profile offers advantages over other beta-blockers, including favorable metabolic effects.

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...